An authorised translation of a security report

Eurofins
Poland

SECURITY REPORT
OF A COSMETIC PRODUCT

BM / 241/02/2017

Date 03/10/2017

Eurofins number: 720-2017-00066821

Manufacturing / Product:
GR-7 a product restoring the natural hair colour

Instruction:
The safety report should be kept with all documents used to prepare this assessment and with individual analytical reports

The documentation should be stored for at least 10 years in a designated place by a designated person.

Eurofins Polska Sp z o.o.
Aleja Wojska Polskiego 90A
82-200 Malbork
Poland

phone: +48 55 272 04 73
fax: +48 55 272 04 75
email: info@eurofins.pl
eurofins.pl

SPECIALIZED DERMATOLOGICAL PRACTISE
Aplications - Tests
MAREK BRZEWSKI, PAWEŁ BRZEWSKI civil partnership
74 Długa Street 31-147 Cracow • Phone (48-12) 267-35-60 (48) 608-472-034 * e-mail: medi@op.pl

SAFTY ASSESSMENT OF COSMETIC PRODUCT

The below named product, having composition, purpose and instruction of usage as declared by its manufacturer, is not hazardous to human health and complies with Directive 76/768/EEC and is created in accordance with Regulation of the European Parliament and Council Regulation (EC) No 1223/2009 of November 2009 on cosmetic products (Official Journal. EU L 342, 22.12.2009, p.59), which took an effect since July 13, 2013.

Product / Product: **GR-7 Product that restores the natural colour of hair**
Producer / Producer GR-7 Sp. z o.o.
Zmyślanka 18
62-860 Opatówek, POLAND

The safety assessor can estimate that, given the present level of knowledge, the product does not show any foreseeable risk to human health under conditions of normal use.

BM / 241/02/2017

NOTE:
1. Each modification of the chemical composition, scope and method of use or the trade name of the product should be reviewed again by the person assessing safety of the product.
2. This opinion does not apply to subjects allergic to any ingredient of the assessed product.

Signature: Date 03/10/2017
Marek Brzewski MD
Paweł Brzewski MD
Stamp: Specialised Dermatology Practise Applications/Tests
MAREK BRZEWSKI, PAWEŁ BRZEWSKI civil partnership
Stamp: Marek Brzewski MD Dermatology Specialist (illegible)
Stamp: Paweł Brzewski MD Dermatologist STD Specialist ph. 600-244-514 2293825

Table of Contents:

10. Information on the cosmetic product

PART B

1. Conclusions from the assessment
2. Warnings and instructions for use placed on the label
3. Reasoning
4. Expert's qualifications and approval of Part B

1. General information on the product

Product name	GR-7 A substance restoring the natural hair colour
Usage characteristics	A substance regaining natural hair colour. Non rinsing product
Producer	GR-7 Sp. z o.o. Zmyślanka 18 62-860 Opatówek, POLAND
Telephone number	+48 572 507 640
Website	www.gr-7.eu
Responsible person	GR-7 Sp. z o.o. Zmyślanka 18 62-860 Opatówek, POLAND

PART A

1. General information about the product

1. Quantitative and qualitative composition of a cosmetic product

1. GR-7 Preparation restoring the natural colour of hair

	Chemical name (trade)	INCI name	CAS Number	EINECS / ELINCS	Function of the component	Content %
1	Water	Aqua	7732-18-5	231-791-2	solvent	up to 100
2	Isopropyl Alcohol	Isopropyl Alcohol	67-63-0	200-661-7	defoamer, scent, solvent, viscosity regulator	16,00
3	Glycerin	Glycerin	56-81-5	200-289-5	denaturant, conditioning hair, humectant, fragrance, skin protection, viscosity regulator	8,00
4	Biotin	Biotin	58-85-5	200-399-3	anti-seborrheic, conditioning hair, conditioning the skin	1,15

6	Inositol	Inositol	87-89-8	201-781-2	anti-static, conditioning hair, humectant	1,10
7	Ammonium Acetate	Ammonium Acetate	631-61-8	211-162-9	buffer	1,10
8	Palmitic Acid	Palmitic Acid	57-10-3	200-312-9	emollient, emulsifying	1,00
9	Polysorbate	Polysorbate 20	9005-64-5	-	emulsifying, surfactant	0,95
10	Tyrosine	Tyrosine	556-02-5/ 556-03-6/ 60-18-4	209-112-6/ 209-113-1/ 200-460-4	Antistatic, conditioning hair, Masking, skin conditioning	0,95
11	Arctium Lappa Root Extract	Arctium Lappa Root	84012-13-5	281-658-8	conditioning the skin	0,60
12	Gallic Acid	Gallic Acid	149-91-7	205-749-9	antioxidant	0,60
13	Sulphur	Sulphur	7704-34-9	231-722-6	anti-dandruff and anti-wrinkles, anti-static, conditioning hair, skin conditioning	0,55
14	Equisetum Hyemale Leaf/Stem Extract	Equisetum Hyemale Leaf/Stem Extract	-	-	skin conditioning	0,40
15	Parfum	Parfum	-	-	parfume	0,015

1.2. Fragrance composition

	Chemical name (trade)	INCI name	Providing party	Content %
1	Parfum	Parfum	Info available with the producer	0,015

2. Physical / chemical properties and stability of the cosmetic product

2.1. Physical / chemical properties of the finished cosmetic product

Density	1,018 g/ml +/-0.112
Viscosity	7,86 cP +/-1.57
Visual qualities	a liquid product of light yellow colour with a yellow precipitate, a characteristic odor of the ingredients used
PH	5.14+7-0.10

2.2 Physical / chemical properties of the substance or mixture

The data used in this point come from Safety Data Sheets provided by the Customer. In the event that there is no information about raw materials from the Customer, appropriate annotations concerning the origin of the source about particular substances are placed.

2.2.1 Water

Propoerties	odorless liquid
PH	neutral (at 20°C)
Density	1,0 g/cm^3
Solubility	in water: completely soluble

2. Isopropyl Alcohol

Information comes from Safety Data Sheet Isopropyl alcohol (Alcohol isopropylicus) FP VI, manufacturer / supplier: Avantor Performance Materials Poland Spółka Akcyjna

Properties	colourless liquid
PH	6,5-7,5
Melting / freezing point	90°C
Boiling temperature	83°C
Ignition temperature	11,7°C (tclosed container)
Relative density	0,79
Solubility	easily soluble in the following materials: cold water and hot water

Self ignition temperature	466°C
Dynamic viscosity	2,2 mPa^s
Molecular weight	60,11 g/mol

2.2.3 Glycerine

Information comes from the Safety Data Sheet Glycerin, manufacturer / supplier: P.W. "Centro- Chem" Sp.j.

Visual qualities	colourless or slightly yellowish liquid
Chemical formula	$C_3H_8O_3$
PH	ok. 5 (100 g/l H_2O w20°C)
Freezing/melting point	18 ° C (solidifies at a much lower temperature)
Boiling temperature and some of boiling temperatures	290°C (1013 hPa, dissolution)
Ignition temperature	177°C
Relative density	1261 kg/m- (20 C)
Solubility	in water: soluble in other substances: soluble in many organic solvents
Self ignition temperature	400°C
Dispersion temperature	>290°C

2.2.2.4 Biotine

Information comes from the Safety Data Sheet (+) - Biotyna, manufacturer / supplier: POCH Spółka Akcyjna

Visual qualities	white solid substance
melting temperature	2280°C

2.2.2.5 Ammonium chloride

Information comes from the Safety Data Sheet of Ammonium chloride, manufacturer / supplier: POCH Spółka Akcyjna

Visual qualities	white solid substance
Molecular weight	53,49
Chemical formula	NH_4Cl
pH	4,5-5,5 (50 g/l H_2O, 20 °C)
Self ignition temperature	>400°C
Density	1,53 g/cm³ (20°C)
Solubility	in water: 370 g / l (20 ° C) in organic solvents: ethanol: 20 g / l (20 ° C)

2.2.6 Inositol

The information comes from the Material Safety Data Sheet Inositol NF 12, manufacturer / supplier: Brenntag Polska Sp. z o.o.

Visual quality	white, odourless, solid substance
Bulk density	630 kg/m³
Molecular weight	180,16
Melting point	223-225°C
Solubility	in water: 250 g/l
PH	5,0-7,0 (r-r 100 g/l)

2.2.7 Ammonium acetate

Information from the Safety Data Sheet Ammonium acetate extra clean, manufacturer / supplier: Merck KGaA

Visual qualities	a colourless solid with a weak acetic acid smell
PH	6.7-7.3 (50 g/l, 25°C)
Melting point	114°C
Density	1,17 g/cm³ (20°C)
Solubility	in water: 1.480 g/l (4°C)
Dispersion temperature	90°C
Bulk density	approx. 410 kg/m³

2.2.8 Palmitic acid

Information comes from Safety Data Sheet Palmitic Acid CZ, manufacturer / supplier: Avantor Performance Materials Poland Spółka Akcyjna

Visual qualities	solid substance
Boiling/melting point	61°C
boiling temperature	63 do 271°C
ignition temperature	206°C (open vessel)
Solubility	partially soluble in the following materials: methanol insoluble in the following materials: hot water
Bulk density	415 kg/m³

2.2.9 Polysorbate 20

The information comes from the Material Safety Data Sheet Polysorbate 20, manufacturer / supplier: Brenntag Polska Sp. z o.o.

Visual qualities	yellow liquid
PH	5,5-7,0(100 g/ g)
Ignition temperature	>149°C
Density	1000-1200 kg/m^3 (25°C)
Solvasbility	w wodzie: rozpuszczalny
Viscosity	300-500 mPa*s (25°C)

2.2.10 tyrosine

The information comes from the L-Tyrosine Safety Data Sheet for biochemistry, manufacturer / supplier: Merck KGaA

Visual quality	colourless powder
PH	ok. 6,5 (0,1 g/)
Melting point	297-298°C (dispersion)
Density	1,46 g/cm^3 (20°C)
Solubility	in water: 0,38 g/l (20°C)
Dispersion temperature	>280°C

2.2.11 Extract of burdock root

The information comes from the Safety Data Sheet of Burdock Root Extract, manufacturer / supplier: MakingCosmetics.com Inc.

Visual quality	light to medium-amber liquid
Ignition temperature	>199°C
Boiling temperature	290°C
Relative density	1,05-1,15 (25°C)
The index of refraction	1,3920-1,5000 (25°C)
Solubility	in water: complete

2.2.12 Gallic acid

The information is from the Material Safety Data Sheet, manufacturer / supplier: Carl Roth GmbH +

Visual quality	whiteish powder
Melting/boiling point	251°C
Solubility	ok. 12 g/l (20°C)

2.2.13 Sulphur

Information comes from the Siarka MSDS, manufacturer / supplier: POCH Spółka Akcyjna

Visual quality	yellowish solid substance
Melting point	111-119°C
Biling point	444°C
Self ignition point	235°C (in the powder form)
Ignition point	168-207°C
Density	1,80-2,06 g/cm^3 (20°C)

Bulk density	400-500 kg/m3
Solivability	in water : unsolible

2.2.14 Extract of winter horsetail

Information comes from Safety Data Sheet Horse Tail Powdered Extract 4: 1, manufacturer / supplier: Natural Sourcing

Visual quality	brown powder
Solubility	partially soluble in water

2.3 Stability of the cosmetic product

Product name	Number of analytics report
GR-7 A substance restoring natural hair colour	AR-17-ST-045059-01

The evaluation of parameters in relation to the control samples took place after a minimum of 5 days for the next 4 cycles with two temperatures of 25 ° C and 5 ° C.

The organoleptic and physicochemical properties during the test were kept in assumed criteria, which excludes the possibility of mass / packaging interaction. There were no changes in the parameters of the packaging, as well as the efficiency and functionality of the bottle cap, no deformation, discolouration observed. The mass loss was within the acceptance criterion, which means that the packaging remained tight under given temperature conditions. Package protects the product against external factors.

As a result of the analysis carried out and based on the results of the research, it was found that the product is compatible with the packaging and it is stabile.

3. Microbiological quality

The microbiological testing of the product indicates that the requirements are met according to point 6 of the Annex to the Ordinance of the Minister of Health of December 23, 2002. on determining procedures for sampling cosmetics and conducting laboratory tests (Journal of Laws 2003 No. 9 item 107)
The quality of the analysed sample corresponds to the scope of the test in accordance with Regulation of the Minister of Health of 23.12.2002; OJ from 2003.Nr 9, item 107.

Permissible level:
Category II Other cosmetics general number of mesophilic aerobic microorganisms:
103 - the maximum acceptance limit is 5x103 units / g.

Quality requirements:
The number of mesophilic aerobic bacteria <1 O units / g
Candida albicans - not present in 0. 1 g
Pseudomonas aeruginosa - not present in 0. 1 g
Staphylococcus aureus - not present 0. 1 g

Results:
The number of mesophilic aerobic bacteria <1 O units / g
Presence of Candida albicans- not present /0.1 g
Presence of Pseudomonas aeruginosa - not present /0.1 g
Presence of Staphylococcus aureus - not present /0.1 g

Results of examination

Name of the Product	Microbiological test
GR-7 A substance restoring the natural hair colour	AR-17-ST-038656-01

The microbiological testing of a cosmetic product should be carried out for each production batch in accordance with the requirements of the Ordinance of the Minister of Health of 23 December 2002.

Name of the Product	Conservation test
GR-7 A substance causing return of natural hair colour	AR-17-ST-045986-01

4. Impurities, traces, information about the material from which the packaging was made
4.1 Information on packaging

Producer (name, address)	Zakład Przetwórstwa Tworzyw Sztucznych WITOPLAST Rudno, 05-340 Kołbiel
Type of packaging	Bottle made of polyethylene (PE)

Microbiological purity	No information about microbiological purity. In case of any doubts, it is necessary to carry out own tests
Stability	No information from the manufacturer regarding stability. However, based on the results of the stability study with the packaging, it can be considered stable under the designated temperature conditions
Possible interactions. impurities	No information about possible interactions or impurities.
Results of compatibility testing of substances with packing	AR-17-ST-045059-01



Height of the sleeve / printable area (vertical)
Length of the sleeve





5. Predictable use of the product

5.1 Normal and rationally predictable use

Product	Usage recommndation	Usage other than becomended
GR-7 Substance restoring the natural colour of hair	GR-7 should be used at least once a day (can be used in the morning and evening for a faster effect). You can see the changes after 7 days of use. a. before each use the bottle must be shaken strongly to mix the content. The liquid should be rubbed in dried scalp (not in the hair) b. b) It is recommended not to wash your head for the first 7 days of gr-7 application. The return to natural hair colour can last from 7 days 21 days depending on the individual structure and condition of the hair. To achieve constant effect use the liquid at least once a week. Immediately after use you can not dry and brush your hair. c. c) The liquid must not be used for facial hair, eyelashes and eyebrows. If it gets into your eyes you should wash them quickly with water. d. During treatment, to make the substance more effective, it is recommended to reduce the consumption of coffee, alcohol and smoking cigarettes. e. For dyed hair one should wait for 2 cm growth.	Product for external use, no other use is expected than that resulting from the name and presentation of the product.

6. Hazard to the effects of the cosmetic product

Type of product	Non - rinceable
Application spot	1/2 of the head surface
Application surface	Scalp
Amount of product to be used	4g
Frequence of usage	1 - 2 times daily

Possible risk areas	eyes
Target group	adults

6.1 SED Value

$$SED = \frac{N \times M \times C \times A}{60}$$

Where,
N- number of applications / day, N = 2
M- mass of the applied product [mg], M = 4000 mg
C - the proportion of the component in the applied product
A- retention coefficient, A = 100%
60- body weight

The SED value was calculated for the maximum possible concentration

	Chemical name (trade)	%	SED
	Chloride		
1	Water	up to 100	133,333
2	Isopropyl Alcohol	16,00	21,333
3	Glycerin	8,00	10,667
4	Biotin	1,15	1,533
5	Ammonium Chloride	1,10	1,467
6	Inositol	1,10	1,467
7	Ammonium Acetate	1,10	1,467
8	Palmitic Acid	1,00	1,333
9	Polysorbate	0,95	1,267
10	Tyrosine	0,95	1,267
11	Arctium Lappa Root Extract	0,60	0,800
12	Gallic Acid	0,60	0,800

13	Sulphur	0,55	0,733
14	Equisetum Hyemale Leaf/Stem Extract	0,40	0,533
15	Parfum	0,015	0,020

7. Exposure to the substance

For ingredients that may be of toxicological significance, the SED exposure dose is calculated first. The SED of a specific component is the amount that passes into the bloodstream (and thus systematica ly exhibits its effect), which depends on the absorption of the skin surface. Since there is no data on the penetration of individual components, one must reckon with total absorption (= 100%).

8. Toxicological profile of the substance

None of the ingredients used by the manufacturer is on the list of substances whose use in cosmetic products is prohibited (Annex ii: Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 November 2009) on cosmetic products.
In the case of cosmetic products, "Margin of Safety" (MoS) is used to evaluate the ingredients. This indicator of component safety assessment is obtained by dividing the highest NO (A) EL value by the calculated SED. To evaluate substances as safe, the Mos must be at least 100.
No NO (A) EL is available for the raw materials used. Therefore, for the assesment, other information on the sensitizing effects of the ingredients and on absorbability of the product was used. Information on possible effects on the skin and mucous membranes has been included.

8.1 Toxicological profile of individual substances

The data used in this point come from Safety Data Sheets provided by the Ordering Party. In the case when there is no information about raw materials from the Ordering Party,
appropriate annotations about the origin of the source by individual
substances are inserted.

8. 1.1 Isopropyl alcohol

Information comes from Safety Data Sheet Isopropyl alcohol (Alcohol isopropylicus) FP VI, manufacturer / supplier: Avantor Performance Materials Poland Spółka Akcyjna
Information on toxicological effects
Acute toxicity
Propan-2-ol:
Skin LD50: 12800 mg / kg (rabbit)
LD50 oral: 5000 mg / kg (rat)
Conclusions / summary: not available
Corrosive / irritating to skin
Propan-2-ol:
Eyes - moderately irritating substance (rabbit, exposure: 24 hours, 100 milligrams) Eyes - moderately irritating substance (rabbit, exposure: 1 O milligrams)
Eyes - highly irritating substance (rabbit, exposure: 100 milligrams)

Skin-causes low irritation (rabbit, exposure: 500 milligrams)
Conclusions / summary: not available
Allergy
Conclusions / summary: not available
Mutagenicity
Conclusions / summary: not available
carcinogenicity
Conclusions / summary: not available
Reproductive toxicity
Conclusions / summary: not available
Specific target organ toxicity - single exposure
Propane-2-ol: category 3, route of exposure: unspecified, organs exposed:
narcotic effect
Specific target organ toxicity - repeated exposure
Conclusions / summary: not available
Danger of inhalation
Unavailable
Information on possible routes of exposure
Eye contact: Irritating to eyes
Inhalation: May cause central nervous system paralysis. Maybe
cause drowsiness or dizziness.
Skin contact: No known significant effects or critical hazards. Ingestion: may cause paralysis of the central nervous system. Irritating
mouth, throat and stomach.
Symptoms related to physical, chemical and toxicological characteristics
Eye contact: serious symptoms may include pain or irritation, tearing, redness
Inhalation: serious symptoms may include: nausea or vomiting, headache,
drowsiness / fatigue, dizziness, unconsciousness
Skin contact: no specific data
Consumption: no specific
Delayed and immediate effects, as well as chronic effects in the case of short and
long-term exposure
Short-term contact
Potential immediate effects: not available
Potential delayed effects: not available
Long-term contact
Potential immediate effects: not available
Potential delayed effects: not available
Potential chronic health effects: not available
Conclusions / summary: not available
General: no known adverse effects or critical hazards.
Carcinogenicity: no known adverse effects or critical hazards. Mutagenicity: no known significant effects or critical hazards.
Teratogenicity: no known adverse effects or critical hazards. Developmental disorders: no reports of adverse effects or critical effects
hazards.
Reproductive disturbances: no known adverse effects or critical effects
hazards.
Other information: not available

8.1.2 Glycerin

Information comes from the Safety Data Sheet Glycerin, manufacturer / supplier: P.W. „ CentroChem Sp.j.
Acute toxicity:
Ingestion Dose: DLS0 (oral, rat): 12600-36000 mg / kg.
Main symptoms: no threat is expected from the intake of small amounts, which occurs during normal handling operations.
However, when consuming large amounts may occur: vomiting, stomach pain, drowsiness, diarrhea, cyanosis.
Inhalation Dose: no data available
Skin Dose: no data available
Irritation / corrosive effect on the skin:
Skin irritation test (rabbit) - no irritation.
Irritation / eye damage: Eye irritation test (rabbit) - no irritation.
Sensitization to the skin or respiratory system: Human test - no performance sensitizing.
Mutagenicity: Genetic toxicity 'in Vitro', Salmonella typhimurium - negative
Carcinogenicity: Did not cause malignant tumors in laboratory animals.
Reproductive Toxicity: No evidence has been demonstrated in animal studies
effects on reproduction. No cases of neonatal defects or other adverse effects on the fetus in animals were observed
laboratory.
Specific target organ toxicity - single exposure: not classified Specific target organ toxicity - repeated exposure: not classified Aspiration risk: not classified

8.1.3. Biotin

Information comes from Safety Data Sheet (+) - Biotin, manufacturer / supplier: POCH
joint-stock company
Toxicological information: no quantitative data available.
Other data: in industrial conditions does not pose a threat.

8.1.4 Ammonium chloride

Information comes from the Safety Data Sheet of Ammonium chloride, manufacturer / supplier: POCH
joint-stock company
Toxicological information: LD50 (oral, rat): 1440 mg / kg, LD50 (oral, mice):
1300 mg / kg, LOLO (oral rats): 1 OOO mg / kg
Other information: after skin contact: symptoms of poor irritation; when consuming: irritation of the mucosa. When eating large amounts - headaches, nausea, loss consciousness; After eye contact: symptoms of irritation; After inhalation: irritation mucous membranes, coughing, shortness of breath.

8.1.5. Inositol

Information comes from Safety Data Sheet Inositol NF 12, manufacturer / supplier: Brenntag Polska Sp. z o.o.
Local action:
- skin: no irritation
- eyes: no irritation
Sensitizing effects: not sensitizing.

8.1.6 Ammonium acetate

Information comes from Safety Data Sheet Octan ammon Extra Clean, producent / supplier: Merck KGaA

Acute oral toxicity - this information is not available

Acute Toxicity - by inhalation - This information is not available

Acute toxicity - after application to the skin - this information is not available

Skin irritation - this information is not available

Eye irritation - this information is not available

Sensitizing effects - this information is not available

Germ cell mutagenicity - this information is not available

Carcinogenicity - this information is not available

Reproductive toxicity - this information is not available

Teratogenicity - this information is not available

Toxic effects on target organs - single exposure - this information is not available

Specific target organ toxicity - repeated exposure - this information is not available

Aspiration hazard - this information is not available

Further information:

After absorbing large amounts:

Muscle symptoms, agitation, convulsions, headache, tremor, nausea, psychosis

The following applies to ammonium salts in general: after ingestion: local irritation symptoms, nausea, vomiting, diarrhea. Systemic effects: after absorption of very large amounts: drop in blood pressure, collapse, disorders of the central nervous system, spasms, dizziness, respiratory paralysis, haemolysis.

Hazardous properties can not be excluded but are unlikely when the product is handled appropriately.

Use in accordance with the principles of health and safety at work.

8.1. 7 Palmitic acid

Information comes from Safety Data Sheet Palmitic Acid CZ, manufacturer / supplier: Avantor Performance Materials Poland Spółka Akcyjna

Information on toxicological effects

Acute toxicity

Conclusion / Summary: Not available.

Corrosive / irritating to skin

Conclusion / Summary: Not available.

Allergy

Conclusion / Summary: Not available.

mutagenicity

Conclusion / Summary: Not available.

carcinogenicity

Conclusion / Summary: Not available.

Reproductive toxicity

Conclusion / Summary: Not available.

Specific target organ toxicity - single exposure

Unavailable.

Specific target organ toxicity - repeated exposure

Unavailable.

Danger of inhalation

Unavailable.
Information on possible routes of exposure
Eye contact No known significant effects or critical hazards. Inhalation No known significant effects or critica hazards.
Contact with skin
No known significant effects or critical hazards.
Ingestion No known significant effects or critical hazards. Symptoms related to physical, chemical and toxicologica characteristics
Eye contact
No specific data.
Inhalation
No specific data.
Contact with skin
No specific data.
Consumption
No specific data.
Delayed and immediate effects, as well as chronic effects in the case of short and long-term exposure
Short-term contact
Potential immediate effects: Not available.
Potential delayed effects: Not available.
Long-term contact
Potential immediate effects: Not available.
Potential delayed effects: Not available.
Potential chronic health effects
Unavailable.
Conclusion / Summary:
Unavailable.
General:
No known significant effects or critical hazards. carcinogenicity
No known significant effects or critical hazards. mutagenicity
No known significant effects or critical hazards. Teratogenicity:
No known significant effects or critical hazards. Developmental disorders
No known significant effects or critical hazards.
Reproductive disorders
No known significant effects or critical hazards.
Other informations :
Unavailable.

8.1.8 Polysorbate 20

The information comes from the Material Safety Data Sheet Polysorbate 20, manufacturer / supplier: Brenntag Polska Sp. z o.o.
Acute oral toxicity: LDS0> 30000 mg / kg (rat)
Acute dermal toxicity: no data available
Acute toxicity (at other applications): no data available
Skin corrosion / irritation: non-irritating
Serious eye damage / eye irritation: not irritating
Respiratory or skin sensitization: not sensitizing
Mutagenic effects on reproductive cells: negative tests Carcinogenicity: no data on the product
Reproductive toxicity: no data on the product

Toxic to organs or systems - single exposure: no data on the product
Toxic to organs or systems - repeated exposure: no data on the product
Aspiration hazard: no data on the product

8.1.9 Tyrosine

The information comes from the L-Tyrosine Safety Data Sheet for biochemistry, manufacturer / supplier: Merck KGaA
Acute Toxicity
LD50 rat> 511 O mg / kg
(External MSDS)
Acute Toxicity - By inhalation
This information is not available
Acute dermal toxicity - this information is not available Skin irritation - this information is not available
Eye irritation - this information is not available
Sensitizing effects - this information is not available
Germ cell mutagenicity - this information is not available. Carcinogenicity - this information is not available
Reproductive toxicity - this information is not available
Teratogenicity - this information is not available
Toxic effects on target organs - single exposure - this information is not available
Specific target organ toxicity - repeated exposure - this information is not available
Aspiration hazard - this information is not available
Further information: this is an endogenous amino acid found in many forms in the natural protein.
No toxicity should be expected if the product is handled appropriately.
Further data:
Use in accordance with the principles of health and safety at work.

8.1.1. Extract of the burdock root
The information comes from the Safety Data Sheet of Burdock Root Extract, manufacturer / supplier: MakingCosmetics.com Inc.
Skin: LD50 value (absorption through the skin, rabbit)> 10 000 mg / kg
Ingestion: The oral dose for LD50 rats is between 17 000 to 27 211 mg / kg Inhalation: The LC50 value for 60 hours in rats is> 4 mg / l. Mutagenicity: In vitro mutagenicity is negative

8.1. 11 Gallic acid
The information comes from the Safety Data Sheet Gallic acid, producer. Supplier: Carl Roth GmbH + Co KG
Acute toxicity: not classified as acutely toxic.
Route of exposure: oral route. LD50: 5000 mg / kg (rat mouse, source: TOXNET) Skin corrosion / irritation: irritating to the skin
Serious eye damage / eye irritation: Irritating to eyes
Skin sensitization or inhalation: not classified as active
sensitizing to the respiratory tract or skin.
Summary of the CMR assessment: not classified as germ cell mutagenic, carcinogenic or toxic to reproduction,
Specific target organ toxicity - single exposure: may cause
irritation of the respiratory tract
Toxic effects on target organs - repeated exposure: not classified as

toxic to the target organs (repeated exposure).
Aspiration hazard: not classified as hazardous
caused by aspiration.
Symptoms related to physical, chemical and toxicological properties
If swallowed: no data available
In case of eye contact: irritating to eyes
In case of entering the respiratory tract: dust may cause irritation of the respiratory tract, coughing
If it gets on the skin: it irritates the skin
Other information: none

8.1.12 Sulfur

Information comes from the Safety Data Sheet of Siarka, producer. Supplier: POCH Spółka Akcyjna
Toxicological information: no quantitative data available
Other data: in industrial conditions it is not toxicological; intake: diarrhea, weakly absorbed

8.1.13 Winter horsetail extract

Information comes from the Safety Data Sheet Horse Tail Powdered Extract 4: 1, producer: supplier Natural Sourcing
Signs and symptoms of exposure: no data available
Toxicological information: no data available
Irritation: no data available
Carcinogenicity: the product does not contain any substances considered by OSHA, NTP, IARC or ACGIH for possibly carcinogenic or suspected carcinogenic to humans.

9. Adverse reaction and serious side effect

Product	Adverse reaction
GR-7 A substance regaining natural hair colour	Not identified

10. Information on the cosmetic product

Dermatological examination of the patches did not show any adverse skin reactions. It can be concluded that in practice the product does not contribute to skin reactions. Findings:

Product	Test number
GR-7 A substance regaining natural hair colour	P/382/01/2017

Product	Test number
GR-7 A substance regaining natural hair colour	AI130/01/2017

Part B

1. Conclusion from the evaluation

The substances used are ingredients often used in the cosmetics industry. In the concentrations given, substances should not cause unwanted skin reactions in people who are not allergic to any of the ingredients.
None of the substances exceed the concentration that may cause an allergic skin reaction. The confirmation of safety is a flap dermatological examination.
Due to the raw materials used, the product can be considered as well preserved and thus meets all microbiological standards.
The product can be considered safe in reasonably foreseeable conditions of use, in accordance with the requirements of Regulation (EC) No. 1223/2009 on Cosmetic Products.

2. Warnings and instructions for use placed on the label

- The liquid must not be used for facial hair, eyebrows and eyebrows. If it gets into your eyes, wash them quickly with water.
- During the course of treatment, to make the liquid more effective, it is recommended to reduce the consumption of coffee, alcohol, as well as discontinuation of smoking.
- In the case of dyed hair, wait for 2 cm of regrowth.
- Do not use the product if you are hypersensitive or allergic to any of the substances it contains.

3. Reasoning

No risk was agreed on the basis of the above data and when used compliant to indications. It should be noted, of course, that with hypersensitivity to any of the product's components, the side effect is not excluded. However, the concentration of all substances does not exceed standards that determine the content of the ingredient as potentially dangerous and that can cause allergic reactions.

4. Expert's qualifications and approval of Part B

Taking into account the general toxicological characteristics of ingredients, chemical composition and exposure, the GR-7 hair colour restoring liquid, a cosmetic product , is under foreseeable use of the product, in a reasonable way, and observing the warnings and the usage instructions, harmless to health.
The data contained in this safety assessment and evaluation (opinions) are based on the current state of knowledge. Any subsequent change to the recipe or the change or addition of data relevant for the safety assessment is tantamount to the cancellation of this report / this assessment.
Confirmation of the product's effectiveness is negligible.
Data on animal testing is insignificant because no animal testing was performed.

SAFETY ASSESOR

Name, surname: Marek Brzewski Paweł Brzewski
Qualifications: MD, specialist in dermatology and STDs
Address: ul. Długa 74 31-147 Kraków

Phone: (48-12) 267 35 60
(48) 608 472 034

Email: mw=edi@op.pl

CD: enclosed

NOTICE
In accordance with the Cosmetics Act of 30 March 2001 (Journal of Laws No. 42, item 473, as amended) and Regulation 1223/2009-EC (OJ L 342 of 22.12.2009, page 59), the manufacturer of cosmetic products is required to keep test reports on: stability, compatibility with packaging, dermatological, safety assessment certificate along with all documents that are necessary to issue such a certificate, certificate confirming solar filter and water resistance (if declared), results from challenge tests and microbiological cleanliness certificates for each production batch. In the case of an application tests, they are made to confirm the product effectiveness (eg. moisturizing, slimming) and confirm the marketing assumptions.

PRODUCT TESTING

Type of test	Report status and number
Safety test	Done
Microbiological test	AR-17-ST-036656-01
Stability and combatibility test	AR-17-ST-045059-01
Patch dermatological test	P/382/01/2017
Application test	N130/01/2017
Challenge test	AR-17-ST-045986-01

Signature
Stamp: Specialised Dermatology Practise Applications/Tests
MAREK BRZEWSKI, PAWEŁ BRZEWSKI civil partnership
Stamp: Marek Brzewski MD Dermatology Specialist (illegible)
Stamp: Pawel Brzewski MD Dermatologist STD Specialist ph. 600-244-514 2293825

Translated from the Polish language document provided to me in an electronic form. Jacek Magnuszewski, sworn translator of English.
Repertory number: 91/19 Kalisz 28th March 2019

Curriculum vitae

Name and surname: doctor of medical science Marek Brzewski MD
Education: higher medical degree
Academic title: MD. Specialist dermatologist and venereologist

Professional experience: 1967 Diploma of a medical doctor at the Medical Academy in Krakow.
1972 1st degree specialisation in dermatology and venereology.

1972 The date of commencement of work at the Jagiellonian University (AM) in the following positions: Assistant, senior lecturer, adjunct, mentor of specialist doctors and scholarship holders of the Ministry of Health. Numerous scientific publications in the field of dermatology and allergology.

1975 Second degree of specialization in dermatology and venereology.
1975 Permanent advisor for cosmetics in Sp. "FLORINA"
1980 Doctor of medical sciences at the Medical Academy in Krakow.
2002 Completion of the course for experts in assessing the safety of cosmetics.
2008 Employment as an associate professor at Małopolska Wyższa Szkoła im. Józef Oietla in the field of Cosmetology.
2010 Appointment as a member of the State Examination Commission in the field of dermatology and venereology.
2012 Completing the training "Safety assessment of cosmetic products in accordance with the requirements of Regulation 1223/2009 / EC

Permanent Cooperation with cosmetic companies, numerous radio and press interviews regarding Cosmetics issues.

Illegible signature

ul. Kujawska 1718 30-042 Kraków Telephone 600 244 514 brzewski@gmail.com
Doctor of Medical Sciences Med. Brzewski Paweł

- Personal information
- Age: 32 years.
- Place of birth: Kraków •
- Parents: Teresa and Marek

Education

1988-1996 Szkoła Podstawowa No. 34 Cracow

1996-2000 I High School - Bartłomiej Nowodworski in Krakow (Biological and chemical profile class)

2000-2006 Medical studies at the Faculty of Medicine, CM UJ

2006-2007 Internship at the Ministry of Interior and Administration in Krakow 2007- Doctoral studies at the Faculty of Medicine CM UJ

2007- Work at the Clinical Department of the Dermatology Clinic

2012- Doctoral dissertation "Study of elongaz and desaturase expression and fatty acid composition in basal cell carcinoma outbreaks" with distinction

2012- specialist dermatologist and venereologist

- Graduation : chemistry with very good grade
- Participation in numerous language courses

Interests and favorite forms of recreation

- Especially skiing, ski-alpinism and mountain biking. Also mountain tours.
- **Languages:** English - fluently
  German - basic level

Practice :

July 2001 Herz und Kreislaufzentrum Rotenburg an der Fulda Germany Practice at Cardiology Ward

July 2002 MSW and A Hospital Practice at the Emergency Department

July and August 2003 Herz und Kreislaufzentrum Rotenburg an der Fulda Germany Practice in the department Cardiac surgery - active participation in heart surgery of various types (by-pass, occtopus, etc.)

Also basic skills in the field of Coronary angiography and cardiac plastic surgery.

August 2003 Ministry of the Interior and Administration of a patient at the children's ward

July 2004 at the Dermatology Clinic at Medizinische Universitat Wien AKH 2006-2007 Internship at the MSW and A Hospital in Krakow

2007- Work at the Clinical Department of the Dermatology Clinic

Voluntary Activity

Action in the Maltese Medical Service

Teaching children to ski in the Maks-INTERSPORT sports club.

Participated in a scientific club at the Chair and Clinic of Dermatology,
Medical College, Jagiellonian University.
Open participation in the scientific circle at the II Chair of Internal Diseases

Certificates and licenses

Safety assesor course - preparing safety reports for cosmetics - Warsaw 2012.

Certificate of the educator entitling to conduct training in the field of HIV and AIDS on behalf of the Minister of Health

Scientific conference "Dermatology in everyday pediatric, internist and family doctor practice" 2004

Scientific and training conference of the Immunology Section of the Polish Dermatological Society "Connective tissue diseases - an interdisciplinary problem - anti-inflammatory and immunosuppressive drugs in the treatment of CTD 2005

Evicience basic medicine course, or clinical decision-making "
practice
the AIS course finished in May 2009,

Participation in the conference, Photobiology in Łódź 2008

VII Winter Dermatology Conference and VII National Alpine Ski Championships January 2009

Interdisciplinary aspects of dermatology" 19-21 March 2009 in
boats

The PTD CONFERENCE OF DERMATOLOGY FOR THE DEVELOPMENT OF OTHER DISCIPLINES OF MEDICINE. SYMPOSIUM OF PEDIATRIC DERMATOLOGY "Wisła 2009

Publications

- Extensive back ulceration due to paintball pallet injury- a report from 24 years old man. lek.med.Paweł Brzewski, lek.e Katarzyna Malec, prof. dr hab. Anna Wojas-Pelc. Medicina Sportiva 15 (2): 88-90,2011.
- Basal cell carcinoma - assessment of mRNA expression for type I and III collagen and MMP-2 and MMP-9 metalloproteinases depending on skin phototypes in oncological patients. Interdisciplinary care of a patient with cancer. Bow. med. Paweł Brzewski, dr hab. n. med. Anna Wojas-Pelt, dr n. biol. Joanna Argasińska, MA Jagoda Drąg, prof. dr hab. k. Jerzy Jaśkiewicz. Krakow 2011. Monography.
- "Diagnosis of skin neoplastic diseases based on the expression of MMP." Interdisciplinary aspects of health sciences, med. Paweł Brzewski, MD Anna Wojas-Pelc, dr n. Biol Joanna Argasińska, MA MA Jagoda Drąg, prof. dr hab. k. Jerzy Jaśkiewicz. Krakow 2011. Monography.
- 2th Munich Internacional Summer Academy of Practical Dermatology 24-29 July 2011- report. Bow. Med. Paweł Brzewski. Dermatologia Estetyczna Vol 13 (5) / 2011.
- Non-hospital infections. Bow. Med. Paweł Brzewski, Dr. med. Andrzej Jaworek, prof. dr hab. Anna Wojas-Pelc. Medycyna Praktyczna Nr 4/2011.
- 8th spring Symposium of the European Academy of Dermatology and venerology Karlove Wary 14-17.04.2011-report. Lek.med. Paweł Brzewski, lek. Agnieszka Nawrocka. Dermatologia Estetyczna Nr 13 (3) / 2011.
- LIPID COMPENSATION DISORDERS IN THE OIL AND SKIN CORRESPONDING IN SELECTED SKIN DISEASES - selected works.

o Disfunction of lipids composition in the epidermis and dermis in some skin diseases-literature review. Bow. med. Paweł Brzewski ', dr hab. n. med. Anna Wojas-Pelc ', dr n. biol. Joanna Argasińska 'mgr. Jagoda Drąg prof. dr hab. n. med. Jerzy Jaśkiewicz 'Aesthetic Dermatology Vol. 12 No. 1/2010

The effectiveness of creatine supplementation in the treatment of congenital creatine metabolism disorders and other neuromuscular disorders. Lucyna Kiszczak, Paweł Brzewski, Mateusz Nowak. Medicina Sportiva Practica, Volume 10, No. 4: 88-94, 2009

18th Congress of the European Academy of Dermatology and Venoreology. (Berlin, Germany October 7-11, 2009) - report. Lek.med. Paweł Brzewski, dr med. Dorota Wielowieyska-Szybińska Dermatology Aesthetic No. 6 (65) / November-December 2009

• "Fatty acids composition and expression of fatty acid metabolism in basal cell carcinoma - preliminary examination." Paweł Brzewski, Anna Wojas-Pelc, Anna Goździalska, Jagoda Drąg, Jerzy JaSkiewicz, Allergology Review 2009 Supl

• NK cell blastonoma - description of skin changes Elżbieta Rup, Paweł Brzewski, Anna Wojas-Pelt, Aleksander Skotnicki, Past Dermatol Allergy XXV, 2008 (Sepia) 221

• A case of children's acne - a review of the literature

regarding therapy. Anna Wojas-Pelc, Joanna Sulowicz, Paweł Brzewski. Bow. 2006, Vol. 63, No. 9, pp. 807-809, illustration, bibliography 31 PR.

• Is sport always healthy? - skin changes in people practicing sports - a review of the literature. Paweł Brzewski, Anna Knafel, Prz. Bow. 2005 T. 62 supl. 1 p. 25, abstr. 98

• IL-12 and IL-18 levels in serum and supernatant from fibroblasts in patients with scleroderma. Anna Knafel, Paweł Brzewski, Prz. Bow. 2005 T. 62 supl. 1 p. 26, abstr. 102

Patients hospitalized in the Department of Dermatology of the Jagiellonian University Medical College due to diseases related to fibrotic disorders in the last five years. Anna Aleksiejenko, Paweł Brzewski, - Prz. Bow. 2004 T. 61 supl. 1 p. 16, abstr. 63

Outline of the history of the Dermatology Clinic of the Jagiellonian University in Krakow. Anna Aleksiejenko, Paweł Brzewski, Prz. Bow. 2004 T. 61 supl. 1 p. 17, abstr. 66

• Moulage (waxy models of dermatoses) in the collection of the Chair of Dermatology at the Jagiellonian University in Krakow. Paweł Brzewski, Anna Alexieenko, Prz. Bow. 2004 T. 61 supl. 1 p. 15, abstr. 59

• Cutaneous leishmaniasis - exotic skin disease. Paweł Brzewski, Anna Aleksiejenko Prz. Bow. 2004 T. 61 supl. 1 p. 16, abstr. 62

Danger and awareness of the risk of viral hepatitis among medical students - the latest research results from 2004. Mikołaj Głowacki, Maciej Stąpór, Paweł Brzewski, Prz. Bow. 2003 T. 60 supl. 2 p. 53, abstr. 213

Adult lumbar puncture: indications, contraindication and complications. (Review of the latest literature) - Brzewski, Głowacki, Jędrychowski - Przegląd lek. 02/2003

• Danger and awareness of the threat of viral hepatitis among medical students - the latest research results. - Jędrychowski, Głowacki, Brzewski - Przegląd lek. 022003

Translated from the Polish language document provided to me in an electronic form. Jacek Magnuszewski, sworn translator of English.

Repertory number: 91/19 Kalisz 28th March 2019